These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22107359)

  • 21. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
    Crauwels H; Vingerhoets J; Ryan R; Witek J; Anderson D
    Antivir Ther; 2012; 17(3):439-46. PubMed ID: 22293086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
    Ye M; Wang L; Fu Q; Zhu Z; Li P; Li T
    HIV Clin Trials; 2010; 11(4):230-7. PubMed ID: 20974578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys.
    Balani SK; Kauffman LR; deLuna FA; Lin JH
    Drug Metab Dispos; 1999 Jan; 27(1):41-5. PubMed ID: 9884307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
    Fletcher CV; Brundage RC; Fenton T; Alvero CG; Powell C; Mofenson LM; Spector SA
    Clin Pharmacol Ther; 2008 Feb; 83(2):300-6. PubMed ID: 17609682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.
    Clarke SM; Mulcahy FM; Tjia J; Reynolds HE; Gibbons SE; Barry MG; Back DJ
    Br J Clin Pharmacol; 2001 Mar; 51(3):213-7. PubMed ID: 11298066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
    Sandkovsky U; Podany AT; Fletcher CV; Owen A; Felton-Coleman A; Winchester LC; Robertson K; Swindells S
    J Antimicrob Chemother; 2017 Jan; 72(1):200-204. PubMed ID: 27655857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects.
    Ji P; Damle B; Xie J; Unger SE; Grasela DM; Kaul S
    J Clin Pharmacol; 2008 Aug; 48(8):948-56. PubMed ID: 18519918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz.
    Mogatle S; Skinner M; Mills E; Kanfer I
    S Afr Med J; 2008 Dec; 98(12):945-9. PubMed ID: 19374071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.
    Ramachandran G; Kumar AK; Vasantha M; Shah I; Swaminathan S
    Indian Pediatr; 2010 Oct; 47(10):890-1. PubMed ID: 21048244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
    Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
    Clin Pharmacokinet; 2011 Aug; 50(8):531-40. PubMed ID: 21740076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
    Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.